TrumpRx to feature ‘limited edition’ antibiotics priced like trading cards

WASHINGTON, Feb 7 – The Trump administration’s direct-to-consumer drug portal, TrumpRx, will begin selling "limited edition" antibiotic courses priced and packaged like collectible trading cards, according to documents reviewed on Friday. Officials said the initiative aims to bring "market excitement and price transparency" to routine infection treatment.

“Each booster will contain three common oral antibiotics, one "holographic" broad-spectrum pill, and a 3.7% chance of a "gold-stamped" hospital-grade vial redeemable at participating emergency rooms.”

Under the new model, antibiotics will be released in rarity tiers ranging from "Common Amoxicillin" to "Legendary UltraBroad Max+" with color-coded foil blister packs. Launch prices will vary from $89 for a five-day generic course to $4,999 for a numbered, first-edition "Founders’ Batch" of intravenous formulations.

"Patients have long complained that drug pricing is confusing and arbitrary, so we are giving them something familiar: card economics," a senior TrumpRx spokesperson said on a press call. "People already understand that a rookie card costs more than a base card; now they’ll understand why their sinus infection is a Series 1 versus a Reprint."

An internal TrumpRx memo describes antibiotics as "a high-potential, under-monetized collectible class" and sets a target for 63% of prescriptions to be fulfilled via "curated booster packs" by 2027. Each booster will contain three common oral antibiotics, one "holographic" broad-spectrum pill, and a 3.7% chance of a "gold-stamped" hospital-grade vial redeemable at participating emergency rooms.

Analysts at Goldman Sachs noted the program could "unlock significant upside from antimicrobial scarcity," projecting a 240% increase in average revenue per infection if patients attempt to complete full "pathogen-specific sets." In a client note, the bank observed that while adherence to treatment guidelines may fall by 19%, "engagement with the brand narrative" could rise by 300%.

TrumpRx said it will also introduce a secondary marketplace, TrumpRx Exchange, where patients can trade unopened blister packs and graded "mint condition" capsules before ingestion. Pricing will update in real time based on manufacturer print runs, regional infection rates and what the memo calls a "Mutation Risk Index" scored on a 0–99 scale.

Pharmaceutical partners will receive quarterly "Hall of Fame" rankings based on revenue per strain, time-to-sellout and the number of social media mentions tagged #InfectionPull. A pilot loyalty program, Infection Points, will let families redeem repeated strep diagnoses for exclusive "clinic-only" cards and limited-run pediatric formulations packaged with collectible presidential artwork.

Regulators have raised preliminary concerns over reports that some patients may delay treatment in hopes of drawing rarer courses in future booster waves, according to people familiar with FDA discussions. However, the White House has framed the initiative as a "data-driven test of infection marketization" and is planning related pilots for vaccine non-fungible tokens and "mortality-linked health savings accounts" as early as next year.